Top news of the week: 08.03.2023.
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA...
The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults and …
Biostage Announces Chairman and CEO Transition
Biostage Announces Chairman and CEO Transition - read this article along with other careers information, tips and advice on BioSpace
National repository for genomic data soon
India’s genomic and biologic data — residing in silos across the country’s research institutions, companies, hospitals and academia in unusable formats — will soon find a home in a national ...
StockWatch: Pfizer Scales Patent Cliff by Pursuing Seagen Deal
Pfizer is the second pharma giant in as many years to attempt a takeover deal for Seagen. Last year Merck & Co. tried, but failed to buy the company, with the would-be buyer and seller ...
23andMe doses first patient in ph2a anti-tumour monotherapy
Human genetics and biopharma company, 23andMe Holding Co has announced it has dosed the first patient in the phase 2a portion of its open-label phase 1/2a study (NCT05199272) …
Red Tree, RA Capital lead $108M infusion into Bicara and its bifunctional I/O drug
Bicara Therapeutics, the Biocon spinout working on a new kind of immunotherapy, has bagged $108 million to push its lead candidate deeper into the clinic. Its top program, BCA101, hits two ...
US IPO Market In 2022 Even Underperformed Normal Years
<p><span>INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out ...
A New Tide for RNA Therapeutics
In the last several years, scientific breakthroughs have led to an influx in research and development around RNA-based therapeutics that offers new hope for applications ranging from ...